2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 55

A Novel Subclass of Intravascular Non-classical, Tissue Resident Synovial Monocyte Is Critical for Rheumatoid Arthritis Pathogenesis

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 532

A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 503

A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 514

A Pooled Analysis of 1-year Clinical Outcomes Among 6-month Responders and Non-responders from Three Randomized Controlled Studies of TNF Inhibitor Biosimilars in Patients with Rheumatoid Arthritis

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 220

A Positive Response to Nonpharmacological Therapies in Patients with Fibromyalgia

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 319

A Pragmatic Randomized Trial to Improve Safe Dosing of Hydroxychloroquine

Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

9:00AM-11:00AM: Abstract Number: 155

A Prospective, Unblinded, Non-randomized Pilot Study Examining the Effect of a Musculoskeletal Immersion Curriculum for First Year Internal Medicine Residents

Education Poster

9:00AM-11:00AM: Abstract Number: 147

A Qualitative Study of Factors That Influence Interest in a Career in Pediatric Rheumatology

Education Poster

9:00AM-11:00AM: Abstract Number: 539

A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 162

A Shared Mental Model for Teaching and Assessing Examination of the Hand, Wrist, and Elbow in the “Training Rheum” Continuing Professional Development Program

Education Poster

9:00AM-11:00AM: Abstract Number: 152

A Shoulder to Lean On: Differences in Shoulder Examinations Between Rheumatology Educators and Fellows

Education Poster

9:00AM-11:00AM: Abstract Number: 517

A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 504

A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 253

A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 731

A Systemic Review of Factors Associated with Systemic Sclerosis-associated Pulmonary Arterial Hypertension (SSc-PAH)

Systemic Sclerosis & Related Disorders – Clinical Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].